P. Bernard

发表

Supervised risk predictor of breast cancer based on intrinsic subtypes.

A. Nobel, J. Marron, E. Mardis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance)

E. Mardis, C. Perou, M. Ellis, 2016, npj Breast Cancer.

Development and verification of the PAM50-based Prosigna breast cancer gene signature assay

E. Mardis, C. Perou, M. Ellis, 2015, BMC Medical Genomics.

Molecular portraits and the family tree of cancer

C. Perou, P. Bernard, C. Chung, 2002, Nature Genetics.

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010, Clinical Cancer Research.

A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer

Mark T. W. Ebbert, Gina R. Petroni, Philip S. Bernard, 2012, Breast Cancer Research and Treatment.

The molecular portraits of breast tumors are conserved across microarray platforms

A. Nobel, C. Fan, C. Perou, 2006, BMC Genomics.

A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer

Mark T. W. Ebbert, Samuel Leung, Charles M Perou, 2010, Clinical Cancer Research.

A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen

E. Mardis, C. Perou, M. Ellis, 2012, Clinical Cancer Research.

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Mark T. W. Ebbert, Charles M Perou, Roy R. L. Bastien, 2012, BMC Medical Genomics.

Intrinsic Subtypes from the PAM50 Gene Expression Assay in a Population-Based Breast Cancer Survivor Cohort: Prognostication of Short- and Long-term Outcomes

P. Bernard, L. Habel, R. Factor, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

Charles M. Perou, Samuel Leung, Philip S. Bernard, 2009, Journal of the National Cancer Institute.

Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial

Mark T. W. Ebbert, Charles M. Perou, Samuel Leung, 2012, Clinical Cancer Research.

Consensus Analysis of Whole Transcriptome Profiles from Two Breast Cancer Patient Cohorts Reveals Long Non-Coding RNAs Associated with Intrinsic Subtype and the Tumour Microenvironment

Angela Cox, N. Camp, A. Cox, 2016, PloS one.

Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer.

C. Perou, T. Nielsen, J. Parker, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

Anastasia Ivanova, Charles M Perou, Katherine A Hoadley, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Zhiyuan Hu, Charles M Perou, Jason I. Herschkowitz, 2007, Genome Biology.

EGFR associated expression profiles vary with breast tumor subtype

Charles M Perou, Melissa A Troester, Katherine A Hoadley, 2007, BMC Genomics.

Response: Re: Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

C. Perou, M. Ellis, S. Leung, 2009 .

Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics

Mark T. W. Ebbert, I. Stijleman, P. Bernard, 2014, Cancer Epidemiology, Biomarkers & Prevention.

of Short-and Long-term Outcomes Population-Based Breast Cancer Survivor Cohort : Prognostication Intrinsic Subtypes from the PAM 50 Gene Expression Assay in a

P. Bernard, L. Habel, R. Factor, 2014 .

Intrinsic Subtypes from the PAM 50 Gene Expression Assay in a Population-Based Breast Cancer Survivor Cohort : Prognostication of Short-and Long-term Outcomes

P. Bernard, L. Habel, R. Factor, 2014 .

Discordant Haplotype Sequencing Identifies Functional Variants at the 2 q 33 Breast Cancer Risk Locus Journal Item

Albright, N. Camp, A. Cox, 2019 .

Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus.

N. Camp, L. Cannon-Albright, A. Cox, 2016, Cancer research.

Discordant Haplotype Sequencing Identifies FunctionalVariantsatthe2q33BreastCancerRisk Locus

N. Camp, L. Cannon-Albright, A. Cox, 2016 .

Membrane Proteins Significantly Restrict Exosome Mobility

Samer M. Al-Hakami, I. Stijleman, P. Bernard, 2017, bioRxiv.

Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression

I. Stijleman, P. Bernard, L. Habel, 2015, BMC Cancer.

POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen.

L. Neumayer, P. Bernard, M. Salama, 2017, Breast.

Breastfeeding, PAM50 tumor subtype, and breast cancer prognosis and survival.

I. Stijleman, P. Bernard, B. Langholz, 2015, Journal of the National Cancer Institute.

Homogeneous multiplex genotyping of hemochromatosis mutations with fluorescent hybridization probes.

P. Bernard, C. Wittwer, J. Kushner, 1998, The American journal of pathology.

Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens.

Roy R. L. Bastien, C. Fan, C. Perou, 2013, The Journal of molecular diagnostics : JMD.

Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia

P. Bernard, G. McMillin, Kibum Kim, 2019, PloS one.

Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia

I. Stijleman, P. Bernard, N. Samadder, 2017, Cancer Prevention Research.

Correction: Statistical modeling for selecting housekeeper genes

C. Perou, J. Quackenbush, P. Bernard, 2008, Genome Biology.

PAM50 breast cancer intrinsic classifier: Clinical validation of a multianalyte laboratory developed test.

C. Fauron, P. Bernard, K. Boucher, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung squamous cell carcinoma mRNA expression subtypes are reproducible , clinically important and correspond to different normal cell types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010 .

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

C. Perou, M. Ellis, T. Nielsen, 2015, The oncologist.

Title: Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically-important and correspond to different normal cell types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010 .

Family Study Designs to Combat Heterogeneity and Identify Multi-Cancer Pleiotropies: The Power of the Utah Population Database

P. Bernard, H. Hanson, J. Doherty, 2020 .

Prognostic Signiﬁcance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Deﬁned Luminal A Breast Cancer

C. Perou, T. Nielsen, J. Parker, 2012 .

High quality and quantity Genome-wide germline genotypes from FFPE normal tissue

L. Cannon-Albright, P. Bernard, Kendal G Cooper, 2011, BMC Research Notes.

Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma

P. Bernard, L. Layfield, N. Goldstein, 2003, Journal of surgical oncology.

Potential Predictive Markers of Benefit from Cetuximab in Metastatic Breast Cancer: An Analysis of Two Randomized Phase 2 Trials.

Mark T. W. Ebbert, C. Perou, K. Hoadley, 2009 .

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Donald A. Berry, Mark T. W. Ebbert, Charles M. Perou, 2013, Breast Cancer Research and Treatment.

Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG.

C. Perou, M. Ellis, T. Nielsen, 2012 .

Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

C. Fan, C. Perou, M. Ellis, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A supervised risk predictor of breast cancer based on biological subtypes

E. Mardis, C. Perou, M. Ellis, 2008 .

Family Study Designs Informed by Tumor Heterogeneity and Multi-Cancer Pleiotropies: The Power of the Utah Population Database

Ken R. Smith, N. Camp, P. Bernard, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Rapid F508del and F508C assay using fluorescent hybridization probes.

C. N. Gundry, P. Bernard, C. Wittwer, 1999, Genetic testing.

Integrated amplification and detection of the C677T point mutation in the methylenetetrahydrofolate reductase gene by fluorescence resonance energy transfer and probe melting curves.

P. Bernard, C. Wittwer, M. Lay, 1998, Analytical biochemistry.

Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation

Matthew D. Wilkerson, Charles M. Perou, Vonn Walter, 2012, PloS one.

The FET3 gene of S. cerevisiae encodes a multicopper oxidase required for ferrous iron uptake

P. Bernard, D. Eide, Liangtao Li, 1994, Cell.

Molecular classification of melanoma using real‐time quantitative reverse transcriptase‐polymerase chain reaction

Roy R. L. Bastien, Brett Milash, Carl T Wittwer, 2005, Cancer.

The LightTyper: high-throughput genotyping using fluorescent melting curve analysis.

P. Bernard, D. J. Eyre, R. Rasmussen, 2003, BioTechniques.

Real-time PCR technology for cancer diagnostics.

Carl T Wittwer, P. Bernard, C. Wittwer, 2002, Clinical chemistry.

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

Mark T. W. Ebbert, L. Neumayer, I. Stijleman, 2011, Nature Medicine.

A multigene assay determines risk of recurrence in patients with triple-negative breast cancer.

P. Bernard, K. Varley, R. Factor, 2019, Cancer research.

Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor

S. Leung, T. Nielsen, I. Stijleman, 2016, Breast Cancer Research and Treatment.

Differentiating Ewing's sarcoma from other round blue cell tumors using a RT-PCR translocation panel on formalin-fixed paraffin-embedded tissues

P. Bernard, C. Coffin, Tracey B Lewis, 2007, Modern Pathology.

Homogeneous amplification and mutation scanning of the p53 gene using fluorescent melting curves.

Haleigh Millward, P. Bernard, W. Samowitz, 2002, Clinical chemistry.

Size and shape characterization of hydrated and desiccated exosomes

P. Bernard, M. Skliar, D. Belnap, 2015, Analytical and Bioanalytical Chemistry.

High‐throughput amplicon scanning of the TP53 gene in breast cancer using high‐resolution fluorescent melting curve analyses and automatic mutation calling

Roy R. L. Bastien, C. Perou, J. Palazzo, 2008, Human mutation.

ESR1 gene amplification in breast cancer: a common phenomenon?

M. Ellis, K. Chin, J. Gray, 2008, Nature Genetics.

Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes.

C. Perou, P. Bernard, D. Shelton, 2012, Genes & cancer.

Color multiplexing hybridization probes using the apolipoprotein E locus as a model system for genotyping.

P. Bernard, C. Wittwer, G. Pritham, 1999, Analytical biochemistry.

Clinical implementation of the intrinsic subtypes of breast cancer.

Charles M Perou, Joel S Parker, Matthew J Ellis, 2010, The Lancet. Oncology.

Cytokeratin profiles of male breast cancers

C. Perou, J. Palazzo, P. Bernard, 2006, Histopathology.

Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay

Zhiyuan Hu, Nicholas P Gauthier, Charles M Perou, 2006, Breast Cancer Research.

Discriminate gene lists derived from cDNA microarray profiles of limited samples permit distinguishing mesenchymal neoplasia ex vivo

P. Bernard, R. Randall, A. Szabo, 2005, Journal of Cancer Research and Clinical Oncology.

Bryan Generates Rare Breast Cancer Subtypes Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and

C. Perou, P. Bernard, D. Shelton, 2013 .

Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor

T. Nielsen, P. Bernard, C. Gilks, 2017, Histopathology.

Chapter 60 – Breast Cancer

P. Bernard, 2013 .

Department of Pathology, Thomas Jefferson University, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors

Jason I. Herschkowitz, Karen E. Rasmussen, C. Perou, 2020 .

Department of Pathology, Thom as Jeffe rson University, Identific ation of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Jason I. Herschkowitz, Karen E. Rasmussen, C. Perou, 2007 .

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard

C. Perou, M. Ellis, T. Nielsen, 2013, Modern Pathology.

State of the science: molecular classifications of breast cancer for clinical diagnostics.

P. Bernard, J. Robison, Laurent Perreard, 2004, Clinical biochemistry.

Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.

Mark T. W. Ebbert, Roy R. L. Bastien, L. Pusztai, 2012, The oncologist.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen

C. Fan, C. Perou, M. Ellis, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies.

S. Chandarlapaty, P. Bernard, B. Sternfeld, 2016, Cancer research.

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

C. Perou, P. Bernard, K. Weber, 2016, Breast Cancer Research and Treatment.

Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues.

Charles M Perou, Steven Bayer, Aniko Szabo, 2007, Clinical chemistry.

Distribution of Molecular Breast Cancer Subtypes in Middle Eastern-Saudi Arabian Women: A Pilot Study

P. Bernard, M. Hadi, D. Al-Tamimi, 2009 .

Multiparametric quantitative phase imaging for real-time, single cell, drug screening in breast cancer

Edward R. Polanco, P. Bernard, B. Welm, 2021, Communications Biology.

Molecular Biomarkers of Sessile Serrated Adenoma/Polyps

M. Bronner, P. Bernard, K. Boucher, 2019, Clinical and Translational Gastroenterology.

Mutation Detection by Fluorescent Hybridization Probe Melting Curves

P. Bernard, A. Reiser, G. Pritham, 2001 .

Homogeneous amplification and variant detection by fluorescent hybridization probes.

P. Bernard, C. Wittwer, 2000, Clinical chemistry.

Clinical Cancer esearch ing , Diagnosis , Prognosis omparison of PAM 50 Intrinsic Subtyping with unohistochemistry and Clinical Prognostic Factors in oxifen-Treated Estrogen Receptor – Positive R ast Cancer

Elaine, C. Perou, M. Ellis, 2010 .

Membrane Proteins Significantly Restrict Exosome Mobility

Samer M. Al-Hakami, I. Stijleman, P. Bernard, 2017, bioRxiv.

Lack of Effect of Metformin on Mammary Carcinogenesis in Nondiabetic Rat and Mouse Models

V. Steele, A. Bode, I. Stijleman, 2015, Cancer Prevention Research.

Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer

P. Bernard, C. Sweeney, B. Caan, 2017, Cancer.

Statistical modeling for selecting housekeeper genes

Charles M Perou, Aniko Szabo, C. Perou, 2004, Genome Biology.

10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer

C. Perou, T. Nielsen, M. Cheang, 2012 .

TRIM29 functions as a tumor suppressor in nontumorigenic breast cells and invasive ER+ breast cancer.

P. Bernard, B. Welm, K. Boucher, 2012, The American journal of pathology.

Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.

C. Perou, I. Stijleman, P. Bernard, 2010, Clinical breast cancer.

Characterization of uncertainty in the classification of multivariate assays: application to PAM50 centroid-based genomic predictors for breast cancer treatment plans

Miguel Martín, Julio C. Facelli, Mark T. W. Ebbert, 2011, Journal of Clinical Bioinformatics.

Differences in molecular features of triple‐negative breast cancers based on the age at diagnosis

P. Bernard, R. Factor, C. Sweeney, 2018, Cancer.

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

C. Perou, T. Nielsen, J. Bergh, 2012 .

Profiling Breast Cancer Using Real-Time Quantitative PCR

P. Bernard, S. Frank, 2004 .

Potential Utility of Pre-Emptive Germline Pharmacogenetics in Breast Cancer

P. Bernard, G. McMillin, Baiju Parikh, 2021, Cancers.

Reparameterization of PAM50 Expression Identifies Novel Breast Tumor Dimensions and Leads to Discovery of a Genome-Wide Significant Breast Cancer Locus at 12q15

N. Camp, I. Stijleman, P. Bernard, 2018, Cancer Epidemiology, Biomarkers and Prevention.

Reparameterization of PAM50 expression identifies novel breast tumor dimensions and leads to discovery of a breast cancer susceptibility locus at 12q15

N. Camp, P. Bernard, Alun Thomas, 2017, bioRxiv.

Reframing Breast Cancer Molecular Subtypes: Modeling Expression Patterns with Orthogonal Dimensions

N. Camp, P. Bernard, Alun Thomas, 2017 .

Identification of Novel Breast Tumor Expression Dimensions within the PAM50 and Discovery of a Breast Cancer Susceptibility Locus at 12q15

N. Camp, P. Bernard, Alun Thomas, 2017 .

Reparameterization of PAM 50 expression identifies novel breast tumor dimensions and leads to discovery of a breast cancer susceptibility locus at 12 q 15

N. Camp, P. Bernard, Alun Thomas, 2017 .

Re-interpretation of PAM50 gene expression as quantitative tumor dimensions shows utility for clinical trials: application to prognosis and response to paclitaxel in breast cancer

N. Camp, J. Herranz, P. Bernard, 2019, Breast Cancer Research and Treatment.

A poor prognosis ER and HER2-negative, nonbasal, breast cancer subtype identified through postneoadjuvant endocrine therapy tumor profiling

J. Olson, C. Perou, M. Ellis, 2008 .

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

C. Perou, T. Vickery, Xiaping He, 2023, Journal of Clinical Oncology.

Prevention of Tumor Growth Driven by PIK3CA and HPV Oncogenes by Targeting mTOR Signaling with Metformin in Oral Squamous Carcinomas Expressing OCT3

V. Steele, A. Bode, I. Stijleman, 2015, Cancer Prevention Research.

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types

Christopher R. Cabanski, C. Perou, D. Hayes, 2010, Clinical Cancer Research.

A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard

C. Perou, M. Ellis, T. Nielsen, 2013, Modern Pathology.

TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer.

C. Perou, K. Hoadley, P. Bernard, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intrinsic Subtypes from PAM50 Gene Expression Assay in a Population-Based Breast Cancer Cohort: Differences by Age, Race, and Tumor Characteristics

Mark T. W. Ebbert, I. Stijleman, P. Bernard, 2014, Cancer Epidemiology, Biomarkers & Prevention.

The most direct way to monitor PCR amplification for quantification and mutation detection

P. Bernard, C. Wittwer, R. Rasmussen, 2022 .

EGFR associated expression profiles vary with breast tumor subtype

C. Fan, C. Perou, K. Hoadley, 2007, BMC Genomics.